These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prevention of respiratory syncytial virus infection in high risk infants.
    Author: Prince AM, Jacobs RF.
    Journal: J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047.
    Abstract:
    The incidence of serious RSV illness in premature infants and in infants with CLD can be reduced. Prophylaxis in infants with CHD and cystic fibrosis seem prudent as well, and clinical trials are currently under way to evaluate the use of Synagis in these high-risk groups. Synagis is preferred for most high-risk children because of its ease of administration, safety and effectiveness. The dose for Synagis is 15 mg/kg i.m. monthly during RSV season.
    [Abstract] [Full Text] [Related] [New Search]